Dr. Eric William Ledin, D.C. Chiropractor Medicare: Not Enrolled in Medicare Practice Location: 2 Evergreen Ln, Unit 7, Hopedale, MA 01747 Phone: 508-478-3158 |
News Archive
While employers may celebrate a low absenteeism rate among their employees, there may be a more serious problem if sick employees are coming to work. "Presenteeism," a new term coined for when employees work while unhealthy, may be even worse for employers and for the healthcare system, costing $160 billion annually in lost productivity, according to healthcare market research firm Kalorama Information, in its new report "The Market for Wellness Programs and Their Impact on Pharmaceutical, Diagnostic and Device Product Markets." The report also notes that presenteeism costs are one of many factors driving usage of wellness programs.
Are you embarrassed to show off your legs this summer? Well you're not alone. Varicose veins affect more than 30 million adults in the US between the ages of 18 to 70, with women twice as likely as men to develop the condition. They are often unattractive, uncomfortable and could cause further medical problems.
Delirium, a form of acute brain dysfunction, is widespread in critically ill patients in lower resourced hospitals, and the duration of delirium predicted both mortality and disability at six months after discharge, according to a study published in PLOS ONE.
The most commonly used treatment for the over 14 million Americans who suffer from Major Depressive Disorder is anti-depressant medication. While such medications bring relief to many, current research suggests that one size may not fit all when it comes to treating depression.
Novexel, a speciality pharmaceutical company focused on the discovery and development of novel antibiotics designed to overcome the significant global problem of microbial resistance, announces today that its most advanced oral antibacterial NXL103 (flopristin/linopristin), has started a Phase II clinical trial in adults with acute bacterial skin and skin structure infections (ABSSSI). The trial is designed to assess the safety and efficacy of NXL103 in comparison to oral linezolid.
› Verified 2 days ago